Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer

Japanese Journal of Cancer and Chemotherapy

Volumn 41, Issue 10, 2014, Pages 1289-1291

  Suzuki, Shuhei ^a   Sakurai, Kenichi ^a   Nagashima, Saki ^a   Hara, Yukiko ^a   Amano, Sadao ^a   Enomoto, Katsuhisa ^a   Makishima, Makoto ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Breast cancer; VEGF

Indexed keywords

BEVACIZUMAB; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR;

BRAIN METASTASIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HORMONE BLOOD LEVEL; HUMAN; MULTIPLE CYCLE TREATMENT; REVIEW; TREATMENT RESPONSE;

EID: 84923354142     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (4)

1. Gasparini G, Toi M, Miceli R et at. Clinical relevance of vascular endothelial growth factor and thymidine phos- phorylase in patients with node-positive breast cancer treated either with adjuvant chemotherapy or hormone- therapy. Canser J Sci Am 5(2): 101-111, 1999.
2. Gordon CJ: Predictive biomarker for bevacizumab: Are wee getting closer ? The Asco Post 2 (17): 2011. http://www.ascopostcom/issues/november-15-2011/predictive-biomarker-for-bevacizumab-are-we-getting-closer.aspx.
3. Yamamoto D, Iwase S, Tsubota Y, et al: Bevacizumab in the treatment of five patients with breast cancer and brain metastasis: Japan Brest Cancer Research Net- work-07 trial. Onco Targets Ther 5:185-189, 2012.
4. Aogi K, Masuda N, Ohno S, et at First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safty results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 129 (3): 829-838, 2011.